pramipexole has been researched along with Drug Withdrawal Symptoms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Brewer, KL; Clemens, S; Dinkins, ML; Lim, SA; Patton, R; Rodgers, HM; Yow, J | 1 |
| Allen, RP; Earley, CJ; Foster, K; Hiranniramol, K; Skeba, P; Wang, A | 1 |
| Arnulf, I; Brion, A; Launois, C; Leu-Semenescu, S | 1 |
| Albrecht, S; Allen, RP; Brenner, SS; Busse, M; Ferini-Strambi, L; Fraessdorf, M; Garcia-Borreguero, D; Hening, W; Högl, B; Poewe, W; Trenkwalder, C | 1 |
| Domino, EF; Jutkiewicz, EM; Ohmura, Y; Zhang, A | 1 |
| Koester, J; Kupsch, A; Oertel, WH; Reess, J; Stiasny-Kolster, K; Trenkwalder, C | 1 |
| Bigal, ME; Rodrigues, GG; Speciali, JG; Stuginski-Barbosa, J | 1 |
2 trial(s) available for pramipexole and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzothiazoles; Double-Blind Method; Female; Humans; Male; Middle Aged; Pramipexole; Quality of Life; Restless Legs Syndrome; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult | 2011 |
Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome.
Topics: Adult; Aged; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Long-Term Care; Male; Middle Aged; Patient Satisfaction; Pramipexole; Quality of Life; Recurrence; Restless Legs Syndrome; Sleep; Substance Withdrawal Syndrome | 2006 |
5 other study(ies) available for pramipexole and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Dopamine D
Topics: Analgesia; Analgesics, Opioid; Animals; Chronic Pain; Dopamine Agonists; Dopamine Antagonists; Drug Combinations; Drug Tolerance; Female; Male; Mice; Mice, Inbred C57BL; Morphine; Neuralgia; Pramipexole; Rats; Rats, Long-Evans; Receptors, Dopamine D1; Receptors, Dopamine D3; Substance Withdrawal Syndrome | 2020 |
Assessment of change in restless legs syndrome symptoms during the acute drug-withdrawal period.
Topics: Analgesics; Analgesics, Opioid; Dopamine Agonists; Electromyography; Female; Gabapentin; Humans; Indoles; Male; Middle Aged; Oxycodone; Polysomnography; Pramipexole; Restless Legs Syndrome; Substance Withdrawal Syndrome | 2018 |
Major depression after withdrawing dopamine agonists in two patients with restless legs syndrome and impulse control disorders.
Topics: Aged, 80 and over; Benzothiazoles; Depressive Disorder, Major; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Humans; Indoles; Male; Middle Aged; Pramipexole; Restless Legs Syndrome; Substance Withdrawal Syndrome | 2013 |
Dopamine D1/5 and D2/3 agonists differentially attenuate somatic signs of nicotine withdrawal in rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Benzazepines; Benzothiazoles; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Implants; Injections, Subcutaneous; Male; Nicotine; Nicotinic Agonists; Pramipexole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Dopamine D5; Substance Withdrawal Syndrome; Tobacco Use Disorder | 2011 |
Burning mouth syndrome responsive to pramipexol.
Topics: Aged; Benzothiazoles; Burning Mouth Syndrome; Corpus Striatum; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Humans; Mouth Mucosa; Parkinson Disease; Pramipexole; Prospective Studies; Receptors, Dopamine D2; Restless Legs Syndrome; Substance Withdrawal Syndrome; Treatment Outcome | 2008 |